- Home
- AACG vs RNXT Comparison
AACG vs RNXT Comparison
Compare AACG & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AACG | RNXT |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.3M | 37.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | AACG | RNXT |
|---|---|---|
| Price | $1.10 | $0.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 23.5K | ★ 350.4K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $39,316,403.00 | $928,000.00 |
| Revenue This Year | N/A | $2,795.35 |
| Revenue Next Year | N/A | $272.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.62 | N/A |
| 52 Week Low | $0.71 | $0.70 |
| 52 Week High | $2.58 | $1.50 |
Technical Indicators
Market Signals| Indicator | AACG | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 63.66 | 42.18 |
| Support Level | $1.07 | $0.97 |
| Resistance Level | $1.17 | $1.04 |
| Average True Range (ATR) | 0.09 | 0.08 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 59.61 | 2.86 |
Price Performance
Historical ComparisonAbout AACG ATA Creativity Global
ATA Creativity Global is an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity. The operating segments of the company are (i) Overseas art study services (ii) Other educational services and (iii) Other services. Majority of its revenue comes from Overseas art study services.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.